April 9th 2024
First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Lapatinib Does Not Improve CRT Outcomes in Non-HPV Head and Neck Carcinoma
October 27th 2023Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.
STAD Fails to Improve Survival Over Radiotherapy Alone in Prostate Cancer
April 30th 2023The addition of short-term androgen deprivation to dose-escalated radiation therapy did not yield a significant difference in quality-of-life outcomes vs radiotherapy alone for those with intermediate-risk prostate cancer, according to an expert from Henry Ford Health Cancer.
Post-Surgery APBI is ‘Attractive’ Option for Low-Risk Early Breast Cancer
March 31st 2023The 10-year cumulative local recurrence rate in patients with early breast cancer receiving accelerated partial breast irradiation with multi-catheter brachytherapy does not significantly differ from those receiving whole-breast irradiation following breast-conserving surgery.
PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate Cancer
March 24th 2023An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.